Home » FDA Awards Orphan Drug Designation to TapImmune Cancer Vaccine
FDA Awards Orphan Drug Designation to TapImmune Cancer Vaccine
TapImmune has scored FDA orphan drug designation for its cancer vaccine TPIV 200 for ovarian cancer.
The multi-epitope peptide vaccine targets folate receptor alpha, a protein overexpressed in multiple cancers, including more than 90 percent of ovarian cancer cells.
Upcoming Events
-
07May
-
14May
-
30May